Trials / Completed
CompletedNCT00971295
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Bial - Portela C S.A. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objective was to investigate whether multiple-dose administration of eslicarbazepine acetate affects the pharmacokinetics of metformin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | 850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days |
| DRUG | Eslicarbazepine acetate |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2007-12-01
- Completion
- 2008-09-01
- First posted
- 2009-09-03
- Last updated
- 2014-12-16
- Results posted
- 2014-12-16
Locations
1 site across 1 country: Portugal
Source: ClinicalTrials.gov record NCT00971295. Inclusion in this directory is not an endorsement.